inclusion criteria: * hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the icu for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. * has laboratory-confirmed novel coronavirus {sars-cov-2} infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr), or other united states food and drug administration (fda)-approved diagnostic assay for covid-19 in any specimen during the current hospital admission prior to randomization. * illness (symptoms of covid-19 of any duration requiring icu level care), and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen. * any one of the following related to covid-19: i. ferritin \> 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) \> 300 units per liter (u/l), iii. d-dimers \> reference range, or iv. c-reactive protein (crp) \> 40 milligram per liter (mg/l). * subject provides informed consent prior to initiation of any study procedures.

inclusion criteria: * hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the icu for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. * has laboratory-confirmed novel coronavirus {sars-cov-2} infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr), or other united states food and drug administration (fda)-approved diagnostic assay for covid-19 in any specimen during the current hospital admission prior to randomization. * illness (symptoms of covid-19 of any duration requiring icu level care), and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen. * any one of the following related to covid-19: i. ferritin \> 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) \> 300 units per liter (u/l), iii. d-dimers \> reference range, or iv. c-reactive protein (crp) \> 40 milligram per liter (mg/l). * subject provides informed consent prior to initiation of any study procedures.

inclusion criteria: hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the icu for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. has laboratory-confirmed novel coronavirus {sars-cov-2} infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other united states food and drug administration (fda)-approved diagnostic assay for covid-19 in any specimen during the current hospital admission prior to randomization. illness (symptoms of covid-19 of any duration requiring icu level care), and the following: radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.), and requiring mechanical ventilation and/or supplemental oxygen. any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). subject provides informed consent prior to initiation of any study procedures.

inclusion criteria: hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the icu for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. has laboratory-confirmed novel coronavirus {sars-cov-2} infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other united states food and drug administration (fda)-approved diagnostic assay for covid-19 in any specimen during the current hospital admission prior to randomization. illness (symptoms of covid-19 of any duration requiring icu level care), and the following: radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.), and requiring mechanical ventilation and/or supplemental oxygen. any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). subject provides informed consent prior to initiation of any study procedures.

inclusion criteria: - hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the icu for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. - has laboratory-confirmed novel coronavirus {sars-cov-2} infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other united states food and drug administration (fda)-approved diagnostic assay for covid-19 in any specimen during the current hospital admission prior to randomization. - illness (symptoms of covid-19 of any duration requiring icu level care), and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen. - any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). - subject provides informed consent prior to initiation of any study procedures.

inclusion criteria: - hospitalized male or female subjects of ≥ 18 years of age at time of screening who are being treated in the icu for covid-19 for not longer than 48 hours or for whom a decision has been made that covid-19 disease severity warrants icu admission. - has laboratory-confirmed novel coronavirus {sars-cov-2} infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other united states food and drug administration (fda)-approved diagnostic assay for covid-19 in any specimen during the current hospital admission prior to randomization. - illness (symptoms of covid-19 of any duration requiring icu level care), and the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.), and 2. requiring mechanical ventilation and/or supplemental oxygen. - any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). - subject provides informed consent prior to initiation of any study procedures.